1.北京中医药大学,北京市朝阳区北三环东路11号,100029
2.北京中医药大学东方医院
3.北京健宫医院
58273677@qq.com
收稿:2025-12-01,
修回:2026-04-28,
录用:2026-01-12,
纸质出版:2026-05-17
移动端阅览
王妍,曹琳琳,郝美玲等.韦氏活血通络方对气虚血瘀型萎缩期非动脉炎性前部缺血性视神经病变患者视功能和眼底血流的影响[J].中医杂志,2026,67(10):1062-1070.
WANG Yan,CAO Linlin,HAO Meiling,et al.Effect of Wei's Huoxue Tongluo Formula(韦氏活血通络方)on Visual Function and Fundus Blood Flow in Treating Atrophic-Stage Non-Arteritic Anterior Ischemic Optic Neuropathy with Qi Deficiency and Blood Stasis[J].Journal of Traditional Chinese Medicine,2026,67(10):1062-1070.
王妍,曹琳琳,郝美玲等.韦氏活血通络方对气虚血瘀型萎缩期非动脉炎性前部缺血性视神经病变患者视功能和眼底血流的影响[J].中医杂志,2026,67(10):1062-1070. DOI: 10.13288/j.11-2166/r.2026.10.007.
WANG Yan,CAO Linlin,HAO Meiling,et al.Effect of Wei's Huoxue Tongluo Formula(韦氏活血通络方)on Visual Function and Fundus Blood Flow in Treating Atrophic-Stage Non-Arteritic Anterior Ischemic Optic Neuropathy with Qi Deficiency and Blood Stasis[J].Journal of Traditional Chinese Medicine,2026,67(10):1062-1070. DOI: 10.13288/j.11-2166/r.2026.10.007.
目的
2
观察韦氏活血通络方对气虚血瘀型萎缩期非动脉炎性前部缺血性视神经病变(NAION)的疗效及可能的机制。
方法
2
82例气虚血瘀型萎缩期NAION患者随机分为治疗组、对照组各41例。治疗组给予韦氏活血通络方颗粒口服(每日2次)及患侧颞浅动脉旁注射灭菌注射用水(每次2 ml、每日1次);对照组给予患侧颞浅动脉旁注射复方樟柳碱注射液(每次2 ml、每日1次)及韦氏活血通络方颗粒模拟剂口服(每日2次),两组均治疗14天。比较两组治疗前及治疗第7、14天最佳矫正视力(BCVA),视盘血管灌流密度(PD)、通量指数(FI),黄斑浅层PD、血管密度(VD)及中医证候评分;比较两组治疗前后视野平均缺损(MD)、平均敏感度(MS),并进行安全性评价。
结果
2
与本组治疗前比较,两组治疗后BCVA、视野MD及MS、中医证候评分均改善(
P
<0.05或
P
<0.01)。治疗组治疗第14天中医证候评分低于对照组(
P
<0.05)。与本组治疗前比较,两组治疗后视盘PD和FI、黄斑浅层PD及VD无明显改善(
P
>0.05),仅治疗第7天对照组黄斑浅层中心凹PD高于治疗组(
P
<0.05)。两组治疗期间未出现严重不良事件。
结论
2
韦氏活血通络方能改善气虚血瘀型萎缩期NAION患者视力、视野等视功能指标和中医证候评分,具有临床安全性,但对视盘及黄斑血流未见明显影响。
Objective
2
To evaluate the efficacy and possible mechanism of
Wei's Huoxue Tongluo Formula
(韦氏活血通络方,WHTF) in treating atrophic-stage non-arteritic anterior ischemic optic neuropathy (NAION) with
qi
deficiency and blood stasis.
Methods
2
A total of 82 atrophic-stage NAION patients with
qi
deficiency and blood stasis were randomly divided into a treatment group and a control group, with 41 cases in each group. The treatment group was given oral administration of WHTF twice a day plus acupoint injection of distilled water 2 ml at Taiyang (EX-HN5) once daily, while the control group received injection of compound anisodine injection 2 ml at Taiyang (EX-HN5) once daily and oral administration of WHTF placebo twice a day. Both groups received treatment for a course of 14 days. The best-corrected visual acuity (BCVA), optic disc perfusion density (PD), flux index (FI), macular superficial PD, vascular density (VD), and traditional Chinese medicine (TCM) syndrome scores were compared between groups before treatment and on day 7 and day 14 of treatment. Additionally, mean defect (MD) and mean sensitivity (MS) of visual fields were measured before treatment and on day 14, along with safety evaluation.
Results
2
After treatment, both groups showed significant improvement in BCVA, visual field MD and MS, and TCM syndrome scores (
P
<0.05 or
P
<0.01). On day 14 of treatment, the TCM syndrome score in the treatment group was significantly lower than that in the control group (
P
<0.05). There was no significant improvement in optic disc PD and FI, and macular superficial PD and VD after treatment in either group (
P
>0.05) except that on day 7 the macular superficial foveal PD in the control group was significantly better than that in the treatment group (
P
<0.05). During the treatment period, no serious adverse events occurred in either group.
Conclusion
2
WHTF can improve the visual function indicators including visual acuity and visual field, as well as TCM syndrome scores in atrophic-stage NAION patients with
qi
deficiency and blood stasis. It shows clinical safety, although it does not appear to have a significant effect on optic disc or macular blood flow.
SALVETAT M L , PELLEGRINI F , SPADEA L , et al . Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview [J]. Vision (Basel, Switzerland) , 2023 , 7 ( 4 ): 72 .
白文浩 , 孙明明 , 徐歆桐 , 等 . 单中心神经眼科住院患者疾病谱及流行病学分析 [J]. 眼科学报 , 2023 , 38 ( 3 ): 190 - 198 .
HATTENHAUER M G , LEAVITT J A , HODGE D O , et al . Incidence of nonarteritic anterior ischemic optic neuropathy [J]. Am J Ophthalmol , 1997 , 123 ( 1 ): 103 - 107 .
XU L , WANG Y , JONAS J B . Incidence of nonarteritic anterior ischemic optic neuropathy in adult Chinese: the Beijing eye study [J]. Eur J Ophthalmol , 2007 , 17 ( 3 ): 459 - 460 .
WANG Y , XU L , JONAS J B . Frequency of non-arteritic anterior ischaemic optic neuropathy in adult Chinese: the Beijing eye study [J]. Br J Ophthalmol , 2007 , 91 ( 3 ): 401 .
林铁柱 , 沈丽君 . 缺血性视神经病变的研究进展 [J]. 国际眼科杂志 , 2024 , 24 ( 9 ): 1443 - 1447 .
于楠 , 邓俊叶 , 彭婕婷 , 等 . 非动脉炎性前部缺血性视神经病变中西医治疗进展 [J]. 中医眼耳鼻喉杂志 , 2022 , 12 ( 1 ): 45 - 48 .
袁晓彤 , 颉瑞萍 , 王永涛 , 等 . 非动脉炎性前部缺血性视神经病变的中西医治疗进展 [J]. 中国中医眼科杂志 , 2022 , 32 ( 1 ): 70 - 72,76 .
贾鑫 , 韩龙辉 , 韩天雨 , 等 . 活血通络法治疗缺血性眼病的临床和实验研究进展 [J]. 中国中医眼科杂志 , 2021 , 31 ( 7 ): 522 - 525 .
朱成义 , 伊琼 , 马金力 , 等 . 活血通络颗粒干预非动脉炎性前部缺血性视神经病变气虚血瘀型的疗效评估 [J]. 北京中医药 , 2016 , 35 ( 11 ): 1058 - 1060 .
夏燕婷 , 郝美玲 , 张陶陶 , 等 . 韦氏活血通络方对气虚血瘀型前部缺血性视神经病变患者视野的影响 [J]. 南京中医药大学学报 , 2020 , 36 ( 2 ): 184 - 188 .
BERRY S , LIN W V , SADAKA A , et al . Nonarteritic anterior ischemic optic neuropathy: cause, effect, and management [J]. Eye Brain , 2017 , 9 : 23 - 28 . doi: 10. 2147/EB.S125311 http://dx.doi.org/10.2147/EB.S125311 .
KARRABI N , HOOSHMANDI S , AMIRABADI A , et al . The role of optical coherence tomography angiography in optic nerve head edema: a narrative review [J]. J Ophthalmol , 2022 , 2022 : 5823345 . doi: 10.1155/2022/5823345 http://dx.doi.org/10.1155/2022/5823345 .
中华医学会眼科学分会神经眼科学组 . 我国非动脉炎性前部缺血性视神经病变诊断和治疗专家共识(2015年) [J]. 中华眼科杂志 , 2015 , 51 ( 5 ): 323 - 326 .
国家中医药管理局医政司 . 24个专业105个病种中医临床路径(试行) [M]. 北京 : 国家中医药管理局医政司 , 2011 : 319 .
中华医学会眼科学分会神经眼科学组 , 中国医药教育协会眼科专业委员会 , 复方樟柳碱临床应用专家共识专家组 . 复方樟柳碱注射液在常见缺血性眼病中应用专家共识(2020版) [J]. 中华实验眼科杂志 , 2020 , 38 ( 7 ): 553 - 561 .
倪昱橙 , 朱溪 , 潘思哲 , 等 . 基于便秘中医临床数据的真实世界研究及处方验证 [J]. 科技导报 , 2024 , 42 ( 21 ): 94 - 101 .
范明明 , 常雨 , 张艮霜 , 等 . 柴术理胃饮治疗功能性消化不良肝胃不和证伴焦虑抑郁临床研究 [J]. 中国中医药信息杂志 , 2023 , 30 ( 6 ): 153 - 157 .
叶钰娟 , 贾静 , 孙燕 , 等 . 针刺对屈光参差性弱视患儿脑部what视觉通路功能连接改变的影响 [J]. 中医杂志 , 2023 , 64 ( 20 ): 2101 - 2108 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 88 - 90 .
MARTIN-GUTIERREZ M P , PETZOLD A , SAIHAN Z B . NAION or not NAION? A literature review of pathogenesis and differential diagnosis of anterior ischaemic optic neuropathies [J]. Eye , 2024 , 38 ( 3 ): 418 - 425 .
廖良 , 韦企平 . 韦企平治疗非动脉炎性前部缺血性视神经病变临证经验 [J]. 中国中医眼科杂志 , 2014 , 24 ( 5 ): 360 - 362 .
宋思敏 , 谢思嘉 , 税小丁 , 等 . 韦企平从络毒论治急性期NAION的临证经验 [J]. 中国中医眼科杂志 , 2025 , 35 ( 1 ): 53 - 58 .
王辉 , 韦企平 , 闫晓玲 , 等 . 基于真实世界数据分析的韦企平治疗NAION用药规律研究 [J]. 中国中医眼科杂志 , 2023 , 33 ( 7 ): 612 - 616,667 .
曹琳琳 . 韦氏活血通络方治疗缺血性视神经病变的疗效及安全性评价 [D]. 北京 : 北京中医药大学 , 2024 .
韦企平 , 孙艳红 . 燕京韦氏眼科学术传承与临床实践 [M]. 北京 : 人民卫生出版社 , 2018 : 335 .
廖良 . 活血化瘀中药对非动脉炎性前部缺血性视神经病变眼血流的影响研究 [D]. 北京 : 北京中医药大学 , 2014 .
朱成义 , 伊琼 , 马金力 , 等 . 活血通络颗粒对缺血性视神经病变的临床研究 [J]. 国际眼科杂志 , 2015 , 15 ( 11 ): 1945 - 1948 .
GANDHI S , PATTATHIL N , CHOUDHRY N . OCTA: essential or gimmick? [J]. Ophthalmol Ther , 2024 , 13 ( 9 ): 2293 - 2302 .
CASTELAIN J , ROMDHANE K , APTEL F , et al . A case-control study of peripapillary microvascular structure by OCT-angiography in non-arteritic ischaemic optic neuropathy at early and resolutive stages [J]. Eye , 2025 , 39 ( 4 ): 771 - 778 .
REN D Z , LI W J , LI C , et al . Optic disc characteristics evaluated with swept source optical coherence tomography angiography (SS-OCTA) in nonarteritic anterior ischemic optic neuropathy (NAION): a cross-sectional study [J]. BMC Ophthalmol , 2025 , 25 ( 1 ): 166 .
赵立宇 , 杨芳 , 吴昌凡 , 等 . 视网膜血管病中黄斑中心凹无血管区的研究进展 [J]. 中华眼底病杂志 , 2021 , 37 ( 2 ): 158 - 162 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号